Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 11/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5056455 | 1.00 | QPCT (0.37) | QPCTKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL14217846 | 0.87 | QPCT (0.35) | QPCTKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL5056989 | 0.87 | QPCT (0.35) | QPCTKDM4EHSD17B10ALDH1A1HPGD | |
| SCHEMBL5063850 | 0.86 | ACVR1 (0.41) | QPCT | |
| SCHEMBL14076493 | 0.86 | ACVR1 (0.41) | QPCT | |
| SCHEMBL5057106 | 0.83 | QPCT (0.41) | QPCTKDM4EHSD17B10HPGDLMNA | |
| SCHEMBL14076705 | 0.83 | QPCT (0.41) | QPCTKDM4EHSD17B10HPGDLMNA | |
| SCHEMBL5058038 | 0.82 | QPCT (0.39) | QPCTKDM4EHSD17B10HPGDLMNA | |
| SCHEMBL14076547 | 0.82 | QPCT (0.39) | QPCTKDM4EHSD17B10HPGDLMNA | |
| SCHEMBL14076426 | 0.81 | QPCT (0.35) | QPCTKDM4EHSD17B10HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008055947-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | QPCT 9/4885KDM4E 3591/4885HSD17B10 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.